Abstract:Therapeutic antibodies have become one of the most influential therapeutics in modern medicine to fight against infectious pathogens, cancer, and many other diseases. However, experimental screening for highly efficacious targeting antibodies is labor-intensive and of high cost, which is exacerbated by evolving antigen targets under selective pressure such as fast-mutating viral variants. As a proof-of-concept, we developed a machine learning-assisted antibody generation pipeline AbGen that greatly accelerates the screening and re-design of immunoglobulins G (IgGs) against a broad spectrum of SARS-CoV-2 coronavirus variant strains. Our AbGen centers around a novel antibody language model (AbLM) that is pretrained on 12 million generic protein domain sequences and fine-tuned on 4,000+ paired VH-VL sequences, with IgG-specific CDR-masking and VH-VL cross-attention. AbLM provides a latent space of IgG sequence embeddings for AbGen, including (a) landscapes of IgGs' activities in neutralizing the wild-type virus are analyzed through structure prediction for IgG and IgG-antigen (viral protein spike's receptor binding domain, RBD) interactions; and (b) landscapes of IgGs' susceptibility in neutralizing variant viruses are predicted through Gaussian process regression, despite that as few as 14 clinical antibodies' responses to variants of concern are available. The AbGen pipeline was applied to over 1300 IgG sequences we collected from RBD-binding B cells of convalescent patients. With experimental validations, AbGen efficiently prioritized IgG candidates against a broad spectrum of viral variants (wildtype, Delta, and Omicron), preventing the infection of host cells in vitro and hACE2 transgenic mice in vivo. Compared to other existing protein language models that require 10-100 times more model parameters, AbLM improved the precision from around 50% to 75% to predict IgGs with low variant susceptibility. Furthermore, AbGen enables structure-based computational protein redesign for selected IgG clones with single amino acid substitutions at the RBD-binding interface that doubled the IgG blockade efficacy for one of the severe, therapy-resistant strains - Delta (B.1.617). Our work expedites applications of artificial intelligence in antibody screen and re-design combining data-driven protein language models and Kriging for antibody sequence analysis and activity prediction, in synergy with physics-driven protein docking and design for antibody-antigen interface analyses and functional optimization.

Prediction of Adeno-Associated Virus Fitness with a Protein Language Based Machine Learning Model

Unsupervised modeling of mutational landscapes of adeno-associated viruses viability

Predictive power of deleterious single amino acid changes to infer on AAV2 and AAV2-13 capsids fitness

Deep diversification of an AAV capsid protein by machine learning

Comprehensive AAV capsid fitness landscape reveals a viral gene and enables machine-guided design

Systematic multi-trait AAV capsid engineering for efficient gene delivery

Identification of Broadly Applicable Adeno-Associated Virus Vectors by Systematic Comparison of Commonly Used Capsid Variants In Vitro

AI4AVP: an antiviral peptides predictor in deep learning approach with generative adversarial network data augmentation

Recent Advances in Machine Learning-Based Models for Prediction of Antiviral Peptides

AAVDiff: Experimental Validation of Enhanced Viability and Diversity in Recombinant Adeno-Associated Virus (AAV) Capsids through Diffusion Generation

Optimal trade-off control in machine learning–based library design, with application to adeno-associated virus (AAV) for gene therapy

Identification of a myotropic AAV by massively parallel in vivo evaluation of barcoded capsid variants

AIVE: accurate predictions of SARS-CoV-2 infectivity from comprehensive analysis

Machine-learning-guided Directed Evolution for AAV Capsid Engineering

DeepAVP: A Dual-Channel Deep Neural Network for Identifying Variable-Length Antiviral Peptides

Generative models for protein sequence modeling: recent advances and future directions

Novel antibody language model accelerates IgG screening and design for broad-spectrum antiviral therapy

wwLearning the language of proteins and predicting the impact of mutations

Evolutionary Non-Linear Modelling for Selecting Vaccines Against Antigenically Variable Viruses.

Viral Immunogenicity Prediction by Machine Learning Methods

Generative AAV capsid diversification by latent interpolation